(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

PREPARAÇÃO FARMACÊUTICA QUE COMPREENDE SAROGLITAZAR E ÁCIDO MIRÍSTICO PARA USO NO TRATAMENTO DE GLOMERULOESCLEROSE SEGMENTAR FOCAL (GESF)

Em ExigênciaInvention PatentPCT · EP2021084254

Application data

Number

112023010340

Type

Invention Patent

Filing

12/03/2021

Publication

06/27/2023

PCT

EP2021084254

Progress at the INPI

Technical opinion to answer
  1. Filing12/03/21
  2. Publication06/27/23
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 06/23/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

DELTA 4 GMBH

AT

Inventors

P. P. (pessoa física)

AT

Technical data

Priority claims

EP

20211662.0 · 12/03/2020

Abstract

PREPARAÇÃO FARMACÊUTICA QUE COMPREENDE SAROGLITAZAR E ÁCIDO MIRÍSTICO PARA USO NO TRATAMENTO DE GLOMERULOESCLEROSE SEGMENTAR FOCAL (GESF). A presente invenção refere-se a uma preparação farmacêutica que compreende saroglitazar e ácido mirístico, ou um de seus sais ou solvatos, para uso no tratamento de glomeruloesclerose segmentar focal (GESF).

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

06/23/2026

RPI 2894

Notificação de entrada na fase nacional - PCT

#1.3

06/27/2023

RPI 2738

Alteração de dados cadastrais

#1.1

06/06/2023

RPI 2735

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.